| Identification | Back Directory | [Name]
AM555S,TAC-101 | [CAS]
125973-56-0 | [Synonyms]
CS-893
AM 555S
AMsilarotene
AM555S,TAC-101
TAC 101; TAC101
AMsilarotene (TAC-101)
4-(3,5-bis(trimethylsilyl)benzamido)benzoic acid
4-[[3,5-Bis(trimethylsilyl)benzoyl]amino]benzoic acid
Benzoic acid,4-[[3,5-bis(trimethylsilyl)benzoyl]amino]-
AsPC-1,Apoptosis,orally active,Retinoid X receptors,cancer,Inhibitor,RAR/RXR,inhibit,RMG-II,MIAPaCa-2,BxPC-3,Am 555S,Amsilarotene,Retinoic acid receptors | [Molecular Formula]
C20H27NO3Si2 | [MDL Number]
MFCD00952173 | [MOL File]
125973-56-0.mol | [Molecular Weight]
385.6 |
| Chemical Properties | Back Directory | [Melting point ]
280℃ (decomposition) | [Boiling point ]
403.3±45.0 °C(Predicted) | [density ]
1.10±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (259.34 mM; Need ultrasonic) | [form ]
Solid | [pka]
4.28±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Amsilarotene (TAC-101; Am 555S), an orally active synthetic retinoid, has selective affinity for retinoic acid receptor α (RAR-α) binding with Ki of 2.4, 400 nM for RAR-α and RAR-β. Amsilarotene induces the apoptotic of human gastric cancer, hepatocellular carcinoma and ovarian carcinoma cells. Amsilarotene can be used for the research of cancer[1][2][3]. | [in vivo]
Amsilarotene (8 mg/kg/day orally for 30 days) inhibits the RMG-II tumor growth in nude mice[2]. | Animal Model: | 6-week-old female BALB/c nu/nu mice with subcutaneous RMG-II tumors[2] | | Dosage: | 8 mg/kg/day | | Administration: | Orally for 30 days | | Result: | The maximal tumor growth-inhibiting effect was seen on day 31 of administration, when there was a 45% reduction of relative tumor volume (RTV). |
| [storage]
Store at -20°C | [References]
[1] Sun SY, et al. Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res. 1997 Nov 1;57(21):4931-9. PMID:9354460
[2] Suzuki N, et al. A novel retinoid, 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101), induces apoptosis of human ovarian carcinoma cells and shows potential as a new antitumor agent for clear cell adenocarcinoma. Gynecol Oncol. 2004 Sep;94(3):643-9. DOI:10.1016/j.ygyno.2004.06.026
[3] Fujimoto K, et al. Induction of cell-cycle arrest and apoptosis by a novel retinobenzoic-acid derivative, TAC-101, in human pancreatic-cancer cells. Int J Cancer. 1999 May 17;81(4):637-44. DOI:10.1002/(sici)1097-0215(19990517)81:43.0.co;2-4 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
Cckinase, Inc.
|
| Tel: |
+1 (732)236-3202 |
| Website: |
www.cckinase.com |
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|